Home » Stocks » APTX

Aptinyx Inc. (APTX)

Stock Price: $2.52 USD -0.05 (-1.95%)
Updated Aug 3, 2021 12:58 PM EDT - Market open
Market Cap 171.12M
Revenue (ttm) 1.75M
Net Income (ttm) -49.57M
Shares Out 68.17M
EPS (ttm) -0.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $2.52
Previous Close $2.57
Change ($) -0.05
Change (%) -1.95%
Day's Open 2.59
Day's Range 2.50 - 2.59
Day's Volume 75,803
52-Week Range 2.30 - 6.47

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

1 week ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

3 weeks ago - Business Wire

When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here.

3 weeks ago - InvestorPlace

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

4 weeks ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

1 month ago - Business Wire

After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program will cons...

1 month ago - Benzinga

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announce...

1 month ago - Business Wire

Top growth penny stocks to watch this year? Check these 3 out right now The post Best Growth Penny Stocks for 2021, Are Small-Caps Worth Watching?

Other stocks mentioned: BIOL, XIN
1 month ago - PennyStocks

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported...

2 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

2 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 months ago - Business Wire

5 Penny Stocks To Watch For The Last Week Of April 2021 The post Best Penny Stocks To Buy Now? 5 For Your Watch List Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS...

Other stocks mentioned: BLRX, CYCN, LCTX, PTN
3 months ago - PennyStocks

Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and deme...

3 months ago - Benzinga

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

3 months ago - Business Wire

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 16.67% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Aptinyx (NASDAQ:APTX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 51.22% year over year to ($0.20), which beat the estima...

4 months ago - Benzinga

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

4 months ago - Business Wire

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

5 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

6 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

7 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

7 months ago - Business Wire

Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

8 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brai...

8 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

9 months ago - Business Wire

The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initiat...

9 months ago - Benzinga

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: SELB, VBIV
9 months ago - The Motley Fool

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

9 months ago - Business Wire

Investors reacted negatively to the company's announcement of a secondary stock offering.

9 months ago - The Motley Fool

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

9 months ago - Business Wire

APTX stock is soaring on Tuesday after Aptinyx announced very positive results from its trial for a treatment for those with PTSD. The post Aptinyx News: Why APTX Stock Is Skyrocketing Today appeared fi...

9 months ago - InvestorPlace

The biotech's PTSD drug hit the mark in a midstage trial.

9 months ago - The Motley Fool

Aptinyx (APTX) is developing a NMDA receptor-targeted candidate, NYX-783, as potential treatment for post-traumatic stress disorder.

9 months ago - Zacks Investment Research

Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results from a Ph...

9 months ago - Market Watch

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

9 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, toda...

10 months ago - Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

11 months ago - Business Wire

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CBAY, EOLS, IBIO, SIEN
11 months ago - 24/7 Wall Street

Aptinyx Inc (APTX) CEO Norbert Riedel on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Aptinyx Inc. (APTX) delivered earnings and revenue surprises of 6.90% and -41.94%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

11 months ago - Business Wire

Aptinyx Inc. (APTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

11 months ago - Zacks Investment Research

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc.

11 months ago - Business Wire

About APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 21, 2018
Stock Exchange
NASDAQ
Ticker Symbol
APTX
Full Company Profile

Financial Performance

In 2020, Aptinyx's revenue was $1.56 million, a decrease of -57.37% compared to the previous year's $3.67 million. Losses were -$50.05 million, -12.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Aptinyx stock is "Buy." The 12-month stock price forecast is 10.29, which is an increase of 308.33% from the latest price.

Price Target
$10.29
(308.33% upside)
Analyst Consensus: Buy